Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medexus Pharmaceuticals Inc (OP: MEDXF )

1.660 +0.040 (+2.47%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,572
Open 1.630
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.620
Today's Range 1.630 - 1.660
52wk Range 1.060 - 2.562
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million 
From Medexus Pharmaceuticals Inc
Via GlobeNewswire

Performance

YTD
-13.54%
-13.54%
1 Month
+39.50%
+39.50%
3 Month
+36.23%
+36.23%
6 Month
-12.63%
-12.63%
1 Year
+3.88%
+3.88%

More News

Read More
Medexus Announces New License Deal for Topical Terbinafine
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces US$58.5 million in New Credit Facilities
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Pharmaceuticals Inc. (TSX: MDP) (OTCQX: MEDXF) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
Medexus to Participate in 35th Annual Roth Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Welcomes Two New Board Members
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Schedules Third Fiscal Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Schedules Second Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
From MicroCap Rodeo
Via AccessWire
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021
From Stock News Now
Via AccessWire
Making a Difference When You Invest? Medexus Says It Improves Lives
Via Benzinga
Sidoti Microcap Virtual Conference
From Sidoti & Company, LLC
Via AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2021
Via Benzinga
Medexus Pharmaceuticals to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021
From Medexus Pharmaceuticals Inc.
Via AccessWire
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
From Stock News Now
Via AccessWire
Topics Cannabis
Exposures Cannabis
Sidoti Microcap Virtual Conference
From Sidoti & Company, LLC
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.